Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Friday morning.

Several other brokerages also recently commented on ABEO. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.02 on Friday. The company has a market cap of $261.70 million, a price-to-earnings ratio of -2.24 and a beta of 1.43. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $5.66 and a 200-day moving average of $5.77.

Institutional Trading of Abeona Therapeutics

Several hedge funds have recently bought and sold shares of ABEO. Adage Capital Partners GP L.L.C. grew its position in Abeona Therapeutics by 20.1% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after purchasing an additional 652,366 shares during the period. abrdn plc grew its position in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the period. Jane Street Group LLC grew its position in Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the period. Western Standard LLC grew its position in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in Abeona Therapeutics in the 4th quarter valued at $520,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.